MAIA Biotechnology reported updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating ateganosine (THIO) in patients with advanced non-small cell lung cancer (NSCLC). The trial demonstrated an 88% disease control rate (DCR) in third-line patients who had progressed after prior immunotherapy and chemotherapy, significantly higher than the 25-35% DCR typically seen with standard chemotherapy.
For the nine months ended September 30, 2026, MAIA Biotechnology reported a net loss of $21.5 million, driven by $23.3 million in operating expenses. The company significantly strengthened its cash position to $21.3 million, up from $8.7 million at year-end 2025, primarily through a public offering that raised approximately $31.0 million.
MAIA Biotechnology, Inc. has prepared and posted a new corporate investor presentation and a summary highlighting its operations and performance to its website. Management intends to use these materials for upcoming presentations to investors and analysts starting October 6, 2026.
Maia Biotechnology Insider Ramiro Guerrero Buys $49.5K of Stock
Ramiro Guerrero bought 37,595 shares of Maia Biotechnology, Inc. at $1.32 a share, worth $49.5K in total on Sep 10, 2026. Shares held after the trade: 773,296 (+5.1%).